Nothing Special   »   [go: up one dir, main page]

Charchaflieh et al., 2015 - Google Patents

Activated complement factors as disease markers for sepsis

Charchaflieh et al., 2015

View PDF @Full View
Document ID
5971239230156256644
Author
Charchaflieh J
Rushbrook J
Worah S
Zhang M
Publication year
Publication venue
Disease markers

External Links

Snippet

Sepsis is a leading cause of death in the United States and worldwide. Early recognition and effective management are essential for improved outcome. However, early recognition is impeded by lack of clinically utilized biomarkers. Complement factors play important roles in …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701

Similar Documents

Publication Publication Date Title
Charchaflieh et al. Activated complement factors as disease markers for sepsis
Cavaillon et al. Sepsis therapies: learning from 30 years of failure of translational research to propose new leads
Park et al. Autophagy primes neutrophils for neutrophil extracellular trap formation during sepsis
Ramadass et al. Molecular mechanisms regulating secretory organelles and endosomes in neutrophils and their implications for inflammation
Braunschweig et al. Human pentraxin 3 binds to the complement regulator c4b-binding protein
Muthas et al. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications
Jongerius et al. Staphylococcal complement evasion by various convertase-blocking molecules
Woehl et al. The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase
Ali et al. Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus
Austermann et al. Alarmins MRP8 and MRP14 induce stress tolerance in phagocytes under sterile inflammatory conditions
Conway Morris et al. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients
Codolo et al. Triggering of inflammasome by aggregated α–synuclein, an inflammatory response in synucleinopathies
Medjeral‐Thomas et al. The complement factor H‐related proteins
Tezel et al. Oxidative stress and the regulation of complement activation in human glaucoma
Christaki et al. The complex pathogenesis of bacteremia: from antimicrobial clearance mechanisms to the genetic background of the host
Gentile et al. Protective immunity and defects in the neonatal and elderly immune response to sepsis
Hou et al. S1PR3 signaling drives bacterial killing and is required for survival in bacterial sepsis
Lesher et al. Properdin in complement activation and tissue injury
Magini et al. Loss of SMPD4 causes a developmental disorder characterized by microcephaly and congenital arthrogryposis
Jodele et al. Tackling COVID‐19 infection through complement‐targeted immunotherapy
Agarwal et al. Binding of Streptococcus pneumoniae endopeptidase O (PepO) to complement component C1q modulates the complement attack and promotes host cell adherence
Sontake et al. Wilms’ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease
Doni et al. Serum amyloid P component is an essential element of resistance against Aspergillus fumigatus
Mook-Kanamori et al. Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis
O'Shea et al. The formin, DIAPH1, is a key modulator of myocardial ischemia/reperfusion injury